ClinicalTrials.gg
CompletedNCT01769170Updated Jul 21, 2021Results posted

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

A Phase 3 interventional study of Brincidofovir and Placebo in CMV, sponsored by Chimerix. Completed at 43 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-21.

Sponsored by Chimerix (part of Jazz Pharmaceuticals) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized, double-blind, placebo-controlled, parallel group, multicenter study compared the effectiveness of oral brincidofovir (BCV) to placebo for the prevention of cytomegalovirus (CMV) infection in stem cell transplant patients who were CMV seropositive but negative for CMV viremia before starting treatment with BCV.

Read the detailed description

This was a randomized, double-blind, placebo-controlled, parallel group multicenter study of oral brincidofovir (BCV) in approximately 450 cytomegalovirus (CMV)-seropositive subjects who had undergone allogeneic hematopoietic stem cell transplantation (HCT). The study consisted of a screening evaluation and a treatment phase of 10 to 14 weeks. Dosing with the study drug (BCV or placebo) was initiated as soon as individual subjects could ingest tablets after transplant but no later than Day 28 post-transplant, and was continued through Week 14. All randomized subjects remained on study and followed the same scheduled study treatment. Study assessments were performed weekly from randomization through completion of the first post-treatment follow-up assessment at Week 15, and every 3 weeks thereafter through Week 24.

02

Conditions studied

  • CMV

Keywords

  • CMV
  • Hematopoietic Stem Cell Transplant Recipients
  • Prevention
03

In context

Lead sponsor

Chimerix is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

First submitted before Chimerix became part of Jazz Pharmaceuticals.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects were required to meet all of the following criteria, as applicable, to be eligible to participate in this study:

  1. Were hematopoietic stem cell transplant (HCT) recipients who had prior evidence of cytomegalovirus (CMV) exposure (CMV-seropositive) before transplantation and were CMV viremia negative at screening and at any other assessments performed prior to the first dose of study drug.
  2. Were aged ≥18 years.
  3. If male, were willing to use an acceptable method(s) throughout the duration of his participation in the study, i.e., through Week 24, when engaging in sexual intercourse with a female subject of .
  4. If female of childbearing potential, i.e., not or surgically sterile, were willing to use 2 acceptable contraceptive methods, 1 of which must have been a barrier method, throughout the duration of her participation in the study, i.e., through Week 24, when engaging in sexual intercourse with a nonsterile male partner.
  5. Were able to begin study drug dosing within 28 days following the qualifying HCT.
  6. Were able to comfortably ingest and absorb oral medication (in the judgment of the investigator and base don lack of significant gastrointestinal events/medical history).
  7. Were willing and able to understand and provide written .
  8. Were willing and able to participate in all required study activities for the entire duration of the study (i.e., through Week 24).

Exclusion criteria

Exclusion Criteria

Subjects who met any of the following criteria, as applicable, were not eligible to participate in this study:

  1. Was pregnant or planned to become pregnant during the anticipated duration of her participation in the study (i.e., through Week 24), or was nursing a child.
  2. Had a positive CMV viremia test (at the designated central virology laboratory or a local virology laboratory) at any time between transplant and the first dose of study drug.
  3. Weighed ≥120 kg (\~265 lbs).
  4. Had (not renal dysfunction or eye disorder) to cidofovir (CDV), brincidofovir (BCV), or its .
  5. Had received (or were anticipated to need treatment with) any of the following:

    • Ganciclovir, valganciclovir, foscarnet, intravenous CDV, or any other anti-CMV therapy (including CMV immune globulin, cell-based therapies, and anti-CMV drugs, e.g., leflunomide, letermovir, or maribavir) at any time post-transplant;
    • Any anti-CMV vaccine at any time;
    • Any other investigation drug within 14 days prior to the first dose of study drug (unless prior approval had been received from the Chimerix medical monitor or designee); or
    • Prior treatment with BCV at any time.
  6. Were receiving of the following drugs on the first dose of study drug or were anticipated to receive any of these drugs at the doses described after the first dose of study drug:

    • Acyclovir orally at >2000 mg total daily dose (TDD) or intravenously at >15 mg/kg TDD;
    • Valaciclovir at >3000 mg TDD; or
    • Leflunomide at any dose.
  7. Were receiving digoxin or ketoconazole (other than topical formulations) at the first dose of study drug or were anticipated to need treatment with either digoxin or ketoconazole during the treatment phase (through Week 14).
  8. Had possible, probably, or definitive CMV disease diagnosed within 6 months prior to first dose of study drug.
  9. Were infected with (based on serology), or had an active virus (HCV) or virus (HBV) infection, as evidence by detectable plasma HCV RNA or HBV DNA, respectively.
  10. Had received another HCT (i.e., other than the qualifying HCT) within 2 years prior to the first dose of study drug.
  11. Had renal insufficiency, as evidence by an estimated (eGFR) \<15 mL/min or required renal dialysis.
  12. Had hepatic abnormalities as evidence by a screening of or aspartate aminotransferase >5 x the (ULN), as reported by the central safety laboratory.
  13. Had a screening total >2 x the ULN and direct bilirubin >1.5 x the ULN, as reported by the central safety laboratory.
  14. Had active solid tumor with the exception of basal cell carcinoma or the underlying condition necessitating HCT (e.g., lymphomas).
  15. Had Stage 2 or higher of the gut or any other GI disease that would have, in the judgment of the investigator, precluded the subject from taking or absorbing oral medication (e.g., clinically active Crohn's disease, ischemic colitis, moderate or severe ulcerative colitis, small bowel resection, ileus, or any condition expected to require abdominal surgery during the course of study participation).
  16. Had any other condition, including abnormal laboratory values, that would have, in the judgement of the investigator, put the subject at increased risk by participating in the study or would have interfered with the conduct or planned analyses of the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
452 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo administered orally twice weekly

    Other: Placebo

  • Active comparator
    Brincidofovir

    100 mg brincidofovir administered orally twice weekly

    Drug: Brincidofovir

Interventions

  • Also known as: BCV, CMX001, Hexadecyloxypropyl cidofovir, HDP-CDV

  • OtherPlacebo
06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant

    Clinically significant cytomegalovirus (CMV) infection was defined by either of the following outcomes: 1. Onset of CMV end-organ disease; or 2. Initiation of anti-CMV-specific preemptive therapy based on documented CMV viremia (as measured by the central virology laboratory) and the clinical condition of the subject. CMV viremia (i.e., the measurement of CMV DNA in plasma) was determined by the designated central virology laboratory at all scheduled visits via quantitative polymerase chain reaction (qPCR) testing using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test.

    Time frame: 24 weeks

Secondary outcomes

  1. Incidence of Clinically Significant CMV Infection Through Week 14

    The incidence of clinically significant cytomegalovirus (CMV) infection through Week 14. Blood and urine for virologic evaluations were collected at screening, pre-dose on the first day of study drug administration, and at pre-specified intervals throughout the treatment phases of the study and sent to a designated central virology laboratory for analysis. Blood samples were used for real-time assay of CMV viremia in plasma using a qPCR assay. Urine samples were stored for possible future retrospective analyses of CMV.

    Time frame: 14 weeks

07

Results

Posted Jan 5, 2021

Participant flow

Participant flow — Overall Study
MilestoneBrincidofovirPlacebo
Started303149
Completed232122
Not completed7127

Outcome measures

PrimaryNumber of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant

Clinically significant cytomegalovirus (CMV) infection was defined by either of the following outcomes: 1. Onset of CMV end-organ disease; or 2. Initiation of anti-CMV-specific preemptive therapy based on documented CMV viremia (as measured by the central virology laboratory) and the clinical condition of the subject. CMV viremia (i.e., the measurement of CMV DNA in plasma) was determined by the designated central virology laboratory at all scheduled visits via quantitative polymerase chain reaction (qPCR) testing using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant
ParticipantsBrincidofovirPlacebo
Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant15578
SecondaryIncidence of Clinically Significant CMV Infection Through Week 14

The incidence of clinically significant cytomegalovirus (CMV) infection through Week 14. Blood and urine for virologic evaluations were collected at screening, pre-dose on the first day of study drug administration, and at pre-specified intervals throughout the treatment phases of the study and sent to a designated central virology laboratory for analysis. Blood samples were used for real-time assay of CMV viremia in plasma using a qPCR assay. Urine samples were stored for possible future retrospective analyses of CMV.

Time frame:
14 weeks
Reported as:
Count of participants · Participants
Incidence of Clinically Significant CMV Infection Through Week 14
ParticipantsBrincidofovirPlacebo
Incidence of Clinically Significant CMV Infection Through Week 147457

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brincidofovir—173/303 (57.1%)302/303 (99.7%)
Placebo—56/149 (37.6%)146/149 (98%)
Most frequent serious events
Showing 10 of 176
Most frequent serious events
EventBrincidofovirPlacebo
Acute graft versus host diseaseImmune system disorders98/3039/149
DiarrhoeaGastrointestinal disorders21/3034/149
PyrexiaGeneral disorders9/3038/149
Clostridium difficile colitisInfections and infestations9/3030/149
Acute kidney injuryRenal and urinary disorders9/3034/149
PneumoniaInfections and infestations5/3034/149
Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/3033/149
Alanine aminotransferase increasedInvestigations6/3031/149
Febrile neutropeniaBlood and lymphatic system disorders6/3031/149
NauseaGastrointestinal disorders5/3031/149
Most frequent other events
Showing 10 of 63
Most frequent other events
EventBrincidofovirPlacebo
DiarrhoeaGastrointestinal disorders184/30354/149
Acute graft versus host diseaseImmune system disorders173/30348/149
Abdominal painGastrointestinal disorders104/30326/149
NauseaGastrointestinal disorders93/30329/149
VomitingGastrointestinal disorders74/30325/149
Decreased appetiteMetabolism and nutrition disorders67/30319/149
FatigueGeneral disorders42/30328/149
RashSkin and subcutaneous tissue disorders43/30328/149
PyrexiaGeneral disorders42/30327/149
Oedema peripheralGeneral disorders52/30318/149

Baseline characteristics

Intent-to-Treat Analysis Set, which included all randomized subjects who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)BrincidofovirPlaceboTotal
Mean53.0 ± 14.2951.9 ± 15.0352.6 ± 14.53
Sex: Female, Male
Sex: Female, Male(Participants)BrincidofovirPlaceboTotal
Female16398261
Male14051191
08

Study locations

43 sites
  • University of California, San Diego-Moores Cancer Center
    La Jolla, California 92093, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of Colorado
    Denver, Colorado 80045, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Winship Cancer Institute-Emory
    Atlanta, Georgia 30322, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • The Universit of Iowa
    Iowa City, Iowa 45229, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Beth Isreal Decaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Harper University Hospital
    Detroit, Michigan 48201, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Hackensack University
    Hackensack, New Jersey 07601, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Mt. Sinai Medical Center
    New York, New York 10029, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Medical College/NY Presbyterial Hospital
    New York, New York 10065, United States
  • Levine Cancer Institute/Carolinas Health
    Charlotte, North Carolina 28204, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • Wake Forest
    Winston-Salem, North Carolina 27517, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • The Jewish Hospital
    Cincinnati, Ohio 45236, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Allegheny-Singer Research Institute
    Pittsburgh, Pennsylvania 15224, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Methodist Healthcare of San Antonio
    San Antonio, Texas 78229, United States
  • University of Utah, Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Intermountain Healthcare
    Salt Lake City, Utah 84143, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Centre Hospitalier Universitaire Sart Tilman Liege
    Brüssel, Liege 4000, Belgium
  • Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • University of Toronto
    Toronto, Ontario M5G2C4, Canada
  • Centre Hospitalier Universitaire de Montreal, Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
09

References and documents

Publications

  • Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME, Foster SA, Nichols WG, Boeckh MJ; SUPPRESS Trial Clinical Study Group. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Feb;25(2):369-381. doi: 10.1016/j.bbmt.2018.09.038. Epub 2018 Oct 4. PubMed 30292744 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2013 to primary completion in Dec 2015, 28 months.

Results were first posted in Jan 2021, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2013
First posted
Jan 16, 2013
StartActual
Aug 2013
Primary completionActual
Dec 2015
CompletionActual
Jan 2016
Results first posted
Jan 5, 2021
Last update
Jul 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01769170
Lead sponsor
Chimerix
Responsible party
Sponsor
First posted
Jan 16, 2013
Start date
Aug 2013
Primary completion
Dec 2015
Completion
Jan 2016
Results posted
Jan 5, 2021
Last update
Jul 21, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brincidofovir

Start the discussion